Nuvalent, Inc. (NUVL) News
Filter NUVL News Items
NUVL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NUVL News Highlights
- NUVL's 30 day story count now stands at 3.
- Over the past 1 day, the trend for NUVL's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest NUVL News From Around the Web
Below are the latest news stories about NUVALENT INC that investors may wish to consider to help them evaluate NUVL as an investment opportunity.
Director Anna Protopapas Sells 5,000 Shares of Nuvalent Inc (NUVL)On December 18, 2023, Director Anna Protopapas executed a sale of 5,000 shares of Nuvalent Inc (NASDAQ:NUVL), according to a recent SEC Filing. |
Chief Development Officer Darlene Noci Sells 40,000 Shares of Nuvalent Inc (NUVL)Nuvalent Inc (NASDAQ:NUVL), a company specializing in the development of precisely targeted therapies for patients with cancer, has reported an insider sale according to a recent SEC filing. |
Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 7:30 a.m. PT in San Francisco. |
Nuvalent Inc (NUVL) Reports Q3 2023 Financial Results and Pipeline ProgressCompany Strengthens Cash Position and Advances Clinical Trials |
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial ResultsNuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline progress and reported third quarter 2023 financial results. |
Insider Sell: Darlene Noci Sells 3,000 Shares of Nuvalent Inc (NUVL)On November 1, 2023, Darlene Noci, the Chief Development Officer of Nuvalent Inc (NASDAQ:NUVL), sold 3,000 shares of the company. |
Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology DayNuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the BMO Virtual BioPharma Spotlight Series: Oncology Day on Wednesday, November 8, 2023, at 1:00 p.m. ET. |
7 Biotech Stocks to Get In Now Before Investors Catch OnBiotech stocks are down, but there are hidden gems among the rubble. |
Why Nuvalent Stock Tanked on TuesdayThe dilution monster stalked the company following the announcement of a new capital-raising effort. |
Nuvalent Announces Pricing of Public Offering of Common StockNuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the pricing of its previously announced underwritten public offering of 5,357,143 shares of Class A common stock at a price to the public of $56.00 per share. All shares are being offered by Nuvalent. The gross proceeds to Nuvalent from the offering, before deducting underwriting discounts, commissions and other |